TY - JOUR
T1 - Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
AU - Pons, Laura
AU - Hernández, Laura
AU - Urbizu, Aintzane
AU - Osorio, Paula
AU - Rodríguez-Martínez, Paula
AU - Castella, Eva
AU - Muñoz, Ana
AU - Sanz, Carolina
AU - Arnaldo, Laura
AU - Felip, Eudald
AU - Quiroga, Vanesa
AU - Tapia, Gustavo
AU - Margelí, Mireia
AU - Fernandez, Pedro Luis
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/6/6
Y1 - 2023/6/6
N2 - Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1–10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
AB - Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1–10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
KW - Breast cancer
KW - HER2+
KW - Neoadjuvant chemotherapy
KW - Triple negative
KW - Breast cancer
KW - Neoadjuvant chemotherapy
KW - HER2+
KW - Triple negative
KW - Breast cancer
KW - Neoadjuvant chemotherapy
KW - HER2+
KW - Triple negative
UR - http://www.scopus.com/inward/record.url?scp=85163886431&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/b1b593b5-4cad-3354-96d9-9dd0420a83bb/
UR - https://portalrecerca.uab.cat/en/publications/77ff4bb8-c438-42a2-8ae0-e823a93d7161
U2 - 10.3390/cancers15123068
DO - 10.3390/cancers15123068
M3 - Article
C2 - 37370679
AN - SCOPUS:85163886431
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 12
M1 - 3068
ER -